You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search
Guidelines & Advice
About Guidelines Email Guidelines Team

An Endorsement of the 2021 Guideline on the Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update

Version: N/A ID: GL END 3-23 Oct 2021
Type of Content: Guidelines & Advice
Document Status: Current
Authors:
G. Kulkarni, J. Brown, R. Breau, C. Morash, The initial Management of Prostate Cancer Guideline Development Group

Guideline Objective

The objectives of this guideline are to assess the optimal initial treatments for men with noncastrate advanced, recurrent, or metastatic prostate cancer. Our recommendations are based on the 2021 guideline on the Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update [1].

Patient Population

Men with noncastrate advanced, recurrent, or metastatic prostate cancer.

Intended Guideline Users

The guideline document will support providers in recommending the most optimal initial treatments for men with noncastrate advanced, recurrent, or metastatic prostate cancer.

Research Questions

CLINICAL QUESTION 1: What are the standard initial treatment options for metastatic noncastrate prostate cancer?

CLINICAL QUESTION 2: Are combination therapies such as combined androgen blockade (castration plus a nonsteroidal antiandrogen) better than castration alone for men with noncastrate locally advanced nonmetastatic prostate cancer?

CLINICAL QUESTION 3: Does early (immediate) androgen deprivation therapy improve outcomes over deferred therapy for men with noncastrate locally advanced nonmetastatic disease?

CLINICAL QUESTION 4: Is intermittent androgen deprivation therapy better than continuous androgen deprivation therapy for men with biochemically recurrent nonmetastatic disease?

pdf download Full Report (PDF) (481.27 KB)